Latest from Sidney Kimmel Cancer Center at Jefferson

Jean Hoffman-Censits, MD, associate professor of medical oncology, Thomas Jefferson University Hospital, Sidney Kimmel Cancer Center, discusses immunotherapy in bladder cancer.
 
Costas Lallas, MD, professor at Sidney Kimmel Medical College, Thomas Jefferson University Hospital, discusses the importance of understanding novel agents such as immunotherapeutic across disciplines in the treatment of genitourinary malignancies.
Costas Lallas, MD, professor at Sidney Kimmel Medical College, Thomas Jefferson University Hospital, discusses multidisciplinary care for genitourinary malignancies.
 
Thomas Jefferson University Hospital (Sidney Kimmel Cancer Center at Jefferson) is ranked No. 20 in the Nation in the cancer specialty, according to US News and World Report.
Costas Lallas, MD, professor at Sidney Kimmel Medical College, Thomas Jefferson University Hospital, discusses challenges with immunotherapy in genitourinary (GU) malignancies.
A team of Sidney Kimmel Cancer Center (SKCC) investigators from Thomas Jefferson University and Drexel University has recently published a new study in the journal Cancer Research that sheds light on a key mechanism of prostate cancer progression.
Two new studies from the laboratory of Dr. Alex Mazo at the Sidney Kimmel Cancer Center at Thomas Jefferson University, along with collaborators from SKCC, the Vickie and Jack Farber Institute for Neuroscience and other institutions, provide new insights into the structure of chromatin and its implications for cellular differentiation.
Leonard Gomella, MD, professor, chair, Department of Oncology, director, Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses ongoing trials of immunotherapy for patients with bladder cancer.
Publication Bottom Border
Border Publication